Rituximab in the treatment of refractory pulmonary sarcoidosis

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1525-1528

  Sweiss, Nadera J ^a   Lower, Elyse E ^b   Mirsaeidi, Mehdi ^c   Dudek, Steven ^c   Garcia, Joe G N ^d   Perkins, David ^c   Finn, Patricia W ^c   Baughman, Robert P ^b  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD19 ANTIBODY; CD45 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RITUXIMAB; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; CELL LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FORCED VITAL CAPACITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; LETTER; LUNG SARCOIDOSIS; MALE; MORTALITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; CLINICAL TRIAL; MIDDLE AGED; PROCEDURES; SARCOIDOSIS, PULMONARY; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SARCOIDOSIS, PULMONARY; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84899870583     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00224513     Document Type: Letter

References (12)

1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
2. Baughman RP, Nunes H. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8: 95-103.
3. Sweiss NJ, Curran J, Baughman RP. Sarcoidosis, role of tumor necrosis factor inhibitors and other biologic agents, past, present, and future concepts. Clin Dermatol 2007; 25: 341-346.
4. Korsten P, Mirsaeidi M, Sweiss NJ. Nonsteroidal therapy of sarcoidosis. Curr Opin Pulm Med 2013; 19: 516-523.
5. Lee NS, Barber L, Akula SM, et al. Disturbed homeostasis and multiple signaling defects in the peripheral blood Bcell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol 2011; 18: 1306-1316.
6. Dall'Aglio PP, Pesci A, Bertorelli G, et al. Study of immune complexes in bronchoalveolar lavage fluids. Respiration 1988; 54: Suppl. 1, 36-41.
7. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
8. Puechal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken) 2012; 64: 331-339.
9. Bomprezzi R, Pati S, Chansakul C, et al. A case of neurosarcoidosis successfully treated with rituximab. Neurology 2010; 75: 568-570.
10. Lower EE, Baughman RP, Kaufman AH. Rituximab for refractory granulomatous eye disease. Clin Ophthalmol 2012; 6: 1613-1618.
11. Belkhou A, Younsi R, El Bouchti I, et al. Rituximab as a treatment alternative in sarcoidosis. Joint Bone Spine 2008; 75: 511-512.
12. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961; 2: 1165-1172.